MENU
CYCC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Cyclacel Pharmaceuticals (CYCC) Ownership - Who owns Cyclacel Pharmaceuticals?
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases... Show more
Industry: #Biotechnology
Profile
Industry
Biotechnology
Address
200 Connell Drive
Phone
+1 908 517-7330
Employees
12
Web
https://cyclacel.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
18.44M
P/E Ratio
0.00
Total Cash
4.28M
Projected Growth
N/A
Total Debt
10K
Revenue
10K
Risk (Beta)
-1.38
Dividend Yield
N/A
Total Cash/Share
1.91
Total Debt/Equity
N/A
Revenue/Share
0.01 USD as % of share price
Fundamentals
CYCC
Capitalization
18.4M
P/E Ratio
0.00
Risk (Beta)
-1.38
Dividend Yield
N/A
Total Cash
4.28M
Total Cash/Share
1.91
Total Debt
10K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0.01%
Revenue
10K
ROE
N/A
Book Value
3.63M
P/B Ratio
5.08
Cash Flow
N/A
Earnings
7.12K
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
2K
Current Ratio
5.77
Current Revenue Per Employee
10714.29
Dividends Per Share - Security
N/A
EBITDA
-10.41M
Float
N/A
Float - Current
N/A
Gross Income Margin
100.00
Revenue To Assets
-102.10
Shares Held By Institutions
1.79K
Shares Outstanding - Current
2.24M
Total Liabilities
770K
Total Volume MTD
N/A
Value
-1
Gain YTD
-90.874
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period.
A.I. Advisor
published General Information
General Information
a developer of mechanism-targeted drugs to treat human cancers
Industry Biotechnology
Profile
Fundamentals
Details
Industry
Biotechnology
Address
200 Connell Drive
Phone
+1 908 517-7330
Employees
12
Web
https://cyclacel.com